Bharat Biotech’s intranasal Covid jab iNCOVACC gets Centre’s nod

The nasal Covid vaccine iNCOVACC from Bharat Biotech has been given the green light by the national government for use as a booster dosage for persons above the age of 18 in the nation’s immunisation programme.

The nasal vaccine can be used as a heterologous booster dose for people who have already received Covishield and Covaxin, according to the Union Health Ministry. Starting today, the vaccination will be accessible through the CoWIN app.

The iNCOVACC has been authorised by the Indian government and will be administered to adults over the age of 18 as a heterologous booster dosage.

Starting today, the vaccine will be a part of the Covid-19 immunisation campaigns and will be accessible in private hospitals. In this context, the CoWIN platform will also be changed.

The nasal Covid vaccine iNCOVACC from Bharat Biotech has been given the green light by the national government for use as a booster dosage for persons above the age of 18 in the nation’s immunisation programme.

The nasal vaccine can be used as a heterologous booster dose for people who have already received Covishield and Covaxin, according to the Union Health Ministry. Starting today, the vaccination will be accessible through the CoWIN app.

The iNCOVACC has been authorised by the Indian government and will be administered to adults over the age of 18 as a heterologous booster dosage.

Starting today, the vaccine will be a part of the Covid-19 immunisation campaigns and will be accessible in private hospitals. In this context, the CoWIN platform will also be changed.

The recombinant adenoviral vectored construct used in the vaccine was created in collaboration with Washington University in St. Louis, whose effectiveness was tested in preclinical tests.

The COVID Suraksha Program of the Department of Biotechnology of the Government of India helped to partially finance product development and clinical testing.